ALDX — Aldeyra Therapeutics, Inc.

Is ALDX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of August 19, 2026

Aldeyra Therapeutics, Inc. (ALDX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $1.55. The rating moved from Neutral to Oversold on August 19, 2026.

See all oversold Healthcare stocks →

AI analysis

Aldeyra Therapeutics, Inc. (ALDX) displays characteristics of a high-risk, clinical-stage biotechnology company: limited near-term revenue, dependence on program milestones, and likely funding needs that create dilution risk. Market dynamics over the past session favored growth cyclicals and showed muted defensive hedging, but sector themes that benefit large biologics manufacturing and diagnostics are only indirectly relevant. Key vulnerabilities include single-program exposure, regulatory and clinical outcome uncertainty, and low liquidity that could amplify negative moves. Near-term price sensitivity will be driven by capital-market activity and any clinical or regulatory updates; absent clear financing or positive data, downside risk and dilution remain material.

Key factors

  • Small-cap clinical-stage profile with limited or uncertain near-term revenue generation
  • Likely constrained cash runway and potential need for dilution or financing
  • High sensitivity to single-program clinical and regulatory outcomes
  • Low trading liquidity and elevated share-price volatility typical of microcap biotechs
  • Sector tailwinds for biologics/CRO demand are indirect and may not materially benefit company fundamentals in the near term
  • Macro environment showing cautious risk-on flows that favor growth cyclicals but not necessarily early-stage biotech financing

Risks

  • Clinical trial failure or disappointing data for lead programs
  • Regulatory setbacks or delays that push timelines and increase cash burn
  • Need to raise capital through equity issuance, diluting existing shareholders
  • Reimbursement, payer coverage, or pricing pressure that would limit commercial upside if approvals are achieved
  • Competition from larger, better-capitalized companies or alternative therapies
  • Low investor attention and thin float may amplify downside on negative news

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for ALDX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.